Equities Analysts Offer Predictions for BMY Q2 Earnings

Bristol Myers Squibb Company (NYSE:BMY) – Research analysts at William Blair lowered their Q2 2025 EPS estimates for shares of Bristol Myers Squibb in a research report issued to clients and investors on Monday, July 14th. William Blair analyst M. Phipps now expects that the biopharmaceutical company will earn $1.03 per share for the quarter, down from their previous estimate of $1.52. William Blair has a “Market Perform” rating on the stock. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.74 per share.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, beating analysts’ consensus estimates of $1.50 by $0.30. Bristol Myers Squibb had a return on equity of 87.62% and a net margin of 11.38%. The firm had revenue of $11.20 billion for the quarter, compared to analysts’ expectations of $10.77 billion. During the same quarter in the prior year, the firm posted ($4.40) earnings per share. The company’s quarterly revenue was down 5.6% on a year-over-year basis.

Other research analysts also recently issued research reports about the stock. Morgan Stanley reduced their price target on shares of Bristol Myers Squibb from $36.00 to $34.00 and set an “underweight” rating on the stock in a research note on Thursday, July 10th. Jefferies Financial Group decreased their price target on shares of Bristol Myers Squibb from $70.00 to $68.00 and set a “buy” rating for the company in a research note on Wednesday, April 23rd. Cantor Fitzgerald reissued a “neutral” rating and issued a $55.00 price objective on shares of Bristol Myers Squibb in a research note on Tuesday, April 22nd. The Goldman Sachs Group restated a “neutral” rating and set a $55.00 price objective (down from $67.00) on shares of Bristol Myers Squibb in a report on Tuesday, April 8th. Finally, UBS Group lowered their target price on Bristol Myers Squibb from $60.00 to $54.00 and set a “neutral” rating for the company in a report on Friday, April 11th. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $57.69.

Bristol Myers Squibb Stock Up 1.6%

NYSE:BMY opened at $47.16 on Wednesday. The company has a market cap of $95.98 billion, a price-to-earnings ratio of 17.66, a price-to-earnings-growth ratio of 2.39 and a beta of 0.36. Bristol Myers Squibb has a twelve month low of $41.20 and a twelve month high of $63.33. The company has a current ratio of 1.28, a quick ratio of 1.17 and a debt-to-equity ratio of 2.65. The stock has a fifty day simple moving average of $47.42 and a 200-day simple moving average of $53.06.

Institutional Trading of Bristol Myers Squibb

A number of institutional investors have recently made changes to their positions in BMY. Pinney & Scofield Inc. acquired a new stake in Bristol Myers Squibb in the fourth quarter worth about $25,000. Park Square Financial Group LLC purchased a new position in shares of Bristol Myers Squibb in the 4th quarter valued at approximately $26,000. Global Wealth Strategies & Associates boosted its stake in Bristol Myers Squibb by 137.5% in the 1st quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 275 shares in the last quarter. Transce3nd LLC purchased a new stake in Bristol Myers Squibb during the 4th quarter worth approximately $28,000. Finally, Harel Insurance Investments & Financial Services Ltd. acquired a new position in Bristol Myers Squibb during the 1st quarter valued at approximately $31,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Insider Buying and Selling

In other news, EVP Samit Hirawat purchased 4,250 shares of the business’s stock in a transaction on Friday, April 25th. The shares were acquired at an average cost of $47.58 per share, with a total value of $202,215.00. Following the completion of the acquisition, the executive vice president owned 83,513 shares of the company’s stock, valued at $3,973,548.54. This trade represents a 5.36% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.09% of the stock is owned by insiders.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 1st. Investors of record on Thursday, July 3rd will be paid a dividend of $0.62 per share. The ex-dividend date of this dividend is Thursday, July 3rd. This represents a $2.48 annualized dividend and a dividend yield of 5.26%. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 92.88%.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.